Corixa to Participate at Needham & Company Biotechnology Conference.Business Editors & Health/Medical Writers BIOWIRE2K Needham & Company Third Annual Biotechnology Conference SEATTLE--(BUSINESS WIRE)--June 15, 2004 Corixa Corporation's (Nasdaq:CRXA) senior vice president and chief financial officer, Michelle Burris, will provide an overview of the company and its current initiatives at the Needham & Company Third Annual Biotechnology Conference to be held at the New York Palace
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York. Ms. Burris' presentation will take place on Thursday, June 17 at 2:30 p.m. ET. The presentation will be webcast live through the Investor's section of Corixa's website (http://www.corixa.com/default.asp?pid=invest) and archived 90 days. About Corixa Corixa is a developer of immunotherapeutics with a commitment to treating and preventing cancer and infectious diseases by understanding and directing the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . On June 30, 2003, Corixa announced that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved BEXXAR for the treatment of patients with CD20 positive, follicular fol·lic·u·lar adj. 1. Relating to, having, or resembling a follicle or follicles. 2. Affecting or growing out of a follicle or follicles. , NHL NHL Non-Hodgkin's lymphoma, see there , with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. In addition to BEXXAR, Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to and through late stage clinical trials. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. . For more information, please visit Corixa's Web site at http://www.corixa.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion